Millipore and Proteome Sciences Announce Licensing Agreement
Proteome Sciences has established a strong portfolio of patent-protected blood biomarkers of Alzheimer’s disease working in collaboration with the Institute of Psychiatry (IoP) at King’s College London. A number of these biomarkers have been independently identified and their relationship to Alzheimer’s disease confirmed by researchers at GlaxoSmithKline.
Millipore will acquire the exclusive right to develop and sell Luminex bead-based panels for research related to the study of Alzheimer’s disease and other cognitive function disorders. Proteome Sciences retains all rights to clinical applications of these biomarkers. Financial terms of the license agreement were not disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.